Britain and America have announced a key bilateral deal that will ensure no duties on British drug exports entering the US market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has committed to raise funding on drugs through the public health system. This commitment guarantees that duties on these crucial products will stay at nothing for a timeframe of the next three years.
This deal comes after recent statements to hike import taxes on patented drug products, with increases floated reaching 100%.
"This agreement between the UK strengthens the worldwide climate for cutting-edge drugs and brings long-overdue fairness to transatlantic medicine commerce," an announcement said.
Trade Significance
Medicines constitute one of the Britain's largest exports to the US, which is clearly the biggest buyer for major companies like GSK and AstraZeneca.
Trade data indicate that in the year to the end of last September, the UK exported drugs worth over eleven billion pounds to the US. This figure represented 17.4% of British export trade in that timeframe.
"This deal secures employment, increases funding and facilitates the UK to become a international leader for biotech and pharma," the Business and Trade Secretary stated.
Key UK Commitments
The agreement involves several key commitments from the British government:
- Revised Affordability Limit: The UK will increase the price threshold at which it deems new therapies to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a target to increase overall health service expenditure on medicines from 0.3% of the national economy to 0.6 percent over the following ten-year period.
- Refund Ceiling: The sum drug companies must return to the NHS to prevent overspending will be restricted at 15%. In the past, refunds exceeded twenty percent.
Recent Tensions
The deal comes amid a ongoing row between the drug companies and the UK government over medicine costs and regulatory access.
These tensions were heightened by arguments that American patients were charged a premium for the identical medicines than people in the other developed nations.
Recently, several significant manufacturing plans in the UK have been paused or scrapped, while major expansions have been announced toward US facilities.
The Science Minister stated that the NHS needed to invest a greater share on treatments, noting that its expenditure on drugs had declined as a proportion of its overall budget over the last ten years.
